Navigation Links
Oxford Finance Corporation Closes $7 Million Debt Facility with Othera Pharmaceuticals
Date:9/26/2007

ALEXANDRIA, Va., Sept. 26 /PRNewswire/ -- Oxford Finance Corporation, one of the nation's leading providers of senior debt to the life science community, today announced it has finalized a $7 million secured loan agreement with Othera Pharmaceuticals, Inc. The debt facility will be used to support Othera's goal to become a leading specialty pharmaceutical company focused on novel, patient-administered formulations for ophthalmology, oncology and inflammatory disease.

"This is one of several opportunities we've had to provide financing to Othera," said J. Alden Philbrick, president and chief executive officer of Oxford. "Our business relationship with Othera began with a $1 million equipment loan in 2004, and we continue to be proud to fuel their innovative small molecule development program."

"The additional financing provided by Oxford will be applied to ongoing research and development efforts for our ophthalmic lead compound, OT-551, which is currently in Phase 2 studies, and our new development program for OT- 304 in thrombosis, oncology and inflammatory disease," said Philip Heifetz, vice president of finance and business development for Othera. "Oxford has demonstrated a strong commitment to Othera, and we look forward to a long and expanded relationship as our products advance through our pipeline."

About Oxford Finance Corporation

Oxford Finance Corporation, a subsidiary of Sumitomo Corporation, is a specialty finance firm providing senior secured loans to public and private life science companies worldwide. For nearly 20 years, Oxford has delivered flexible financing solutions to its clients, enabling them to maximize their equity by leveraging their assets. In recent years, Oxford has originated over $600 million in loans, with lines of credit ranging from $100 thousand to $20 million. Oxford is headquartered in Alexandria, Virginia, with additional offices in California and Massachusetts. For more information, visit http://www.oxfordfinance.com.

About Othera Pharmaceuticals, Inc.

Founded in 2002, Othera Pharmaceuticals, Inc. is a privately-held, specialty pharmaceutical company located in Exton, PA. Othera is focused on developing novel, patient-administered formulations for ophthalmology, oncology and inflammatory diseases. Othera is developing topical eye drops for age-related diseases, including some of the leading causes of blindness. Othera is also developing a novel set of orally-administered compounds which may address severe medical conditions including cancer, thrombosis and chronic inflammatory disease. More information on Othera Pharmaceuticals is available on the company's website at http://www.othera.com


'/>"/>
SOURCE Oxford Finance Corporation
Copyright©2007 PR Newswire.
All rights reserved

Related biology technology :

1. Early Stage: Step 11 - Other forms of finance
2. Merge Healthcare hires new VP of finance
3. Joint Finance blocks Doyle ethanol measure
4. Third Wave shuffles finance, sales management
5. Finance Committee rejects extra tax on Internet buys
6. Two Milwaukee finance IT firms agree to exchange check images
7. An analysis of Wisconsins new venture capital and early stage finance programs
8. Trouble-shooting: Misincorporation or low fidelity
9. Roche Diagnostics Corporation
10. Roche Diagnostics Corporation
11. Promega Corporation: Wisconsins quiet innovator
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/12/2017)... ... October 12, 2017 , ... They ... a complex biological network, a depiction of a system of linkages and connections ... Korkin, PhD, associate professor of computer science at Worcester Polytechnic Institute (WPI) and ...
(Date:10/12/2017)... SARASOTA, FL (PRWEB) , ... ... ... Inc. (RPS®) today announces publication of a United States multicenter, prospective clinical ... single use, disposable, point-of-care diagnostic test capable of identifying clinically significant acute ...
(Date:10/12/2017)... Diego, CA (PRWEB) , ... ... ... (https://www.onramp.bio/ ) has launched Rosalind™, the first-ever genomics analysis platform specifically ... all bioinformatics complexity. Named in honor of pioneering researcher Rosalind Franklin, who ...
(Date:10/11/2017)... ... ... wash is a basic first aid supply for any work environment, but most personal eye ... first if a dangerous substance enters both eyes? It’s one less decision, and likely quicker ... eye piece. , “Whether its dirt and debris, or an acid or alkali, getting anything ...
Breaking Biology Technology:
(Date:4/5/2017)... , April 4, 2017 KEY FINDINGS ... to expand at a CAGR of 25.76% during the ... is the primary factor for the growth of the ... https://www.reportbuyer.com/product/4807905/ MARKET INSIGHTS The global stem ... technology, application, and geography. The stem cell market of ...
(Date:3/30/2017)... -- Trends, opportunities and forecast in this market to ... AFIS, iris recognition, facial recognition, hand geometry, vein recognition, ... industry (government and law enforcement, commercial and retail, health ... and by region ( North America , ... , and the Rest of the World) ...
(Date:3/24/2017)... -- Research and Markets has announced the addition of ... - Industry Forecast to 2025" report to their offering. ... The Global Biometric Vehicle ... around 15.1% over the next decade to reach approximately $1,580 million ... estimates and forecasts for all the given segments on global as ...
Breaking Biology News(10 mins):